America's Best Nonprofits
  1. Home
  2. Medical Research
  3. Atlanta, GA
  4. Rheumatology Research Foundation

Rheumatology Research Foundation

Rheumatology Research Foundation is ranked #2 of 7 medical research organizations in Atlanta, GA, with an America's Best Score of 78 out of 100, based on its 2025 Form 990.

  • Atlanta, GA
  • Tax-exempt since 1988
  • EIN: 58-1654301
rheumresearch.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
78OF 100 #2 of 7 in Atlanta ranked medical research organizations How this score is calculated

Organization summary

Rheumatology Research Foundation is a 501(c)(3) organization, classified under Medical Research (NTEE H110). Contributions are tax-deductible.

3379 Peachtree Rd Ne Ste 700, Atlanta, GA 30326-1419

Among the 12 scored medical research organizations in Atlanta, Rheumatology Research Foundation holds 51.3 months of operating reserves (peer median 7.8 months), runs a typical yearly deficit of 22.4% (peers: deficit of 3.0%), and has grown spending 1.3% a year (peers: grown spending 13.1% a year).

In fiscal year 2025 it reported $19,785,814 in revenue and $17,070,676 in expenses, with contributions making up 71.2% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

The mission of the Rheumatology Research Foundation is to advance research and training to improve the health of people with rheumatic diseases.

Main program · fiscal year 2025

  • FOUNDATION PROGRAMS SUPPORT RESEARCH INVESTIGATING THE BROAD SPECTRUM OF RHEUMATIC DISEASES, INCLUDING but not limited to: JUVENILE IDIOPATHIC ARTHRITIS, OSTEOARTHRITIS, PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS, SCLERODERMA, SPONDYLOARTHROPATHIES, SYSTEMIC LUPUS ERYTHEMATOSUS, AND VASCULITIS. PLEASE SEE SCHEDULE O FOR A CONTINUATION OF PROGRAM SERVICES. The Rheumatology Researc… Read more

    FOUNDATION PROGRAMS SUPPORT RESEARCH INVESTIGATING THE BROAD SPECTRUM OF RHEUMATIC DISEASES, INCLUDING but not limited to: JUVENILE IDIOPATHIC ARTHRITIS, OSTEOARTHRITIS, PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS, SCLERODERMA, SPONDYLOARTHROPATHIES, SYSTEMIC LUPUS ERYTHEMATOSUS, AND VASCULITIS. PLEASE SEE SCHEDULE O FOR A CONTINUATION OF PROGRAM SERVICES. The Rheumatology Research Foundation maintains an extensive awards and grants portfolio, with 22 support mechanisms for rheumatologists and rheumatology health professionals in the U.S. Each grant application contains very specific eligibility and review criteria (details regarding these requirements are available at www.rheumresearch.org). All applications undergo rigorous peer review in their assigned study section, and are scored and ranked according to the review criteria and overall merit of the proposal. All study section recommendations are sent to the Foundation's Scientific Advisory Council for qualification before being presented (blinded) to the Foundation Board of Directors for final approval. After the awards are made, all recipients are required to complete funding contracts with institutional sign-off, and must also submit annual reports on their progress, including financial reconciliation and assurance of compliance with Foundation policies (available on the website). All reports are reviewed by the Foundation's Scientific Advisory Council to ensure compliance with programmatic, scientific, fiscal, and administrative polices and requirements. If a recipient is found to be in compliance and making reasonable progress (i.e. meeting project benchmarks), the next year of funding is approved for disbursement. If not, the award may be terminated. Such programmatic oversight allows for excellent stewardship of Foundation funds. In additional to regular oversight as described above, portfolio review are conducted every five years to ensure that funding mechanisms are effectively meeting the Foundation's goals outlined in the strategic plan. In addition, the Rheumatology Research Foundation abides by the following conflict of interest guidelines: Guidelines for awarding of Foundation awards and grants I. The Foundation will not permit and external entities to select (or influence the selection of) recipients of Foundation awards or grants. II. The Foundation will appoint independent committees to select recipients of Foundation awards or grants based on peer review of grant applications. III. The Foundation will not require recipients of Foundation awards or grants to meet with external entities. IV. The Foundation will not permit any external entity that supports Foundation awards or grants to require intellectual property rights or royalties arising out of the grant-funded research. V. The Foundation will not permit any external entity that supports Foundation awards or grants to control or influence manuscripts that arise from the grant-funded research. The Foundation provides funding to help recruit students and residents into the subspecialty and supports investigators and practitioners working in the field of rheumatology. Grants are awarded for different training opportunities, from undergraduate students to established investigators, building a more capable, robust team of rheumatology professionals around the nation. In the last five years, researchers receiving Foundation funding have published 451 papers, received $133.5M in related NIH funding, and given 69 scientific presentations at the ACR Convergence meeting. The Foundation is a 501(c)(3) charitable organization dedicated to advancing treatment for people living with rheumatic disease and is the largest private funding source of rheumatology research and training in the United States. The organization has received a 4-star rating, the highest offered by Charity Navigator, for sixteen consecutive years based on good governance, sound fiscal management, and commitment to accountability and transparency. The organization has committed over $243M directly to research and training since it was founded in 1985 by the granting of 4,982 individual awards.

    $14,441,757 spent

Where each dollar went · fiscal year 2025

Of every dollar it spent, 85¢ went to programs, 3¢ to management and 12¢ to fundraising.

  • Programs $14,441,757
  • Management $645,443
  • Fundraising $1,983,476

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score78 / 100
Rank in Atlanta#2 of 7
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves51.3 mo; 1.0 mo in cash25 / 25
Financial balance (median margin)−22.4%5 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth+1.3% / yr8.2 / 15
Track record38 years10 / 10
Debt load4.5% of assets10 / 10
Total78.2 → 78
Spending on programs
Not scored; America's Best needs 65%+
85%Meets

Compared with Atlanta peers

MeasureThis organizationPeer median
Operating reserves51.3 mo7.8 mo
Typical margin−22.4%−3.0%
Spending growth+1.3% / yr+13.1% / yr
Debt load4.5%17.8%

Peers: the 12 Atlanta medical research organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$19,785,814Fiscal year 20252022: $7,906,91920222023: $13,039,46520232024: $13,965,88120242025: $19,785,8142025
Expenses$17,070,676Fiscal year 20252022: $16,411,50320222023: $17,402,76920232024: $17,398,19220242025: $17,070,6762025
Total assets$76,434,619Fiscal year 20252022: $70,647,39820222023: $70,496,54320232024: $70,729,61020242025: $76,434,6192025
Total liabilities$3,409,238Fiscal year 20252022: $1,870,67120222023: $501,81820232024: $1,605,57020242025: $3,409,2382025
Fiscal year ending June 2025
Revenue$19,785,814
Expenses$17,070,676
Net income$2,715,138
Net assets$73,025,381

Notable sources of revenue

Percent of total revenue
Contributions$14,078,487
Program services$0
Investment income$5,707,327
Other (net)$0

Assets / debt

Total assets$76,434,619
Total liabilities$3,409,238
Net assets$73,025,381

Compensation

Not in our extract for this year.

Fiscal year ending June 2024
Revenue$13,965,881
Expenses$17,398,192
Net income−$3,432,311
Net assets$69,124,040

Notable sources of revenue

Percent of total revenue
Contributions$8,533,094
Program services$0
Investment income$5,432,787
Other (net)$0

Assets / debt

Total assets$70,729,610
Total liabilities$1,605,570
Net assets$69,124,040

Compensation

Not in our extract for this year.

Fiscal year ending June 2023
Revenue$13,039,465
Expenses$17,402,769
Net income−$4,363,304
Net assets$69,994,725

Notable sources of revenue

Percent of total revenue
Contributions$12,592,717
Program services$0
Investment income$853,682
Other (net)−$406,934

Assets / debt

Total assets$70,496,543
Total liabilities$501,818
Net assets$69,994,725

Compensation

Officers and key employees$47,300
Share of expenses0.3%
Fiscal year ending June 2022
Revenue$7,906,919
Expenses$16,411,503
Net income−$8,504,584
Net assets$68,776,727

Notable sources of revenue

Percent of total revenue
Contributions$6,103,597
Program services$0
Investment income$816,681
Other (net)$986,641

Assets / debt

Total assets$70,647,398
Total liabilities$1,870,671
Net assets$68,776,727

Compensation

Officers and key employees$59,844
Share of expenses0.4%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?